TrialCurveCA209-7AL: reconstructed Kaplan–Meier curves
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Signal Transduct Target Ther. 2025 Sep 29;10:317. doi: 10.1038/s41392-025-02408-3 |
|---|---|
| DOI | 10.1038/s41392-025-02408-3 |
| Registry | NCT04085250 |
| Phase | Phase 2 |
| Conditions | Stage III Non-small-cell Lung Cancer |
| Interventions | Neoadjuvant therapy, Chemotherapy concurrent with radiotherapy, Radiotherapy, Nivolumab, Observation |
| Sponsor | Sun Yat-sen University |
| Enrolment | 264 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Randomized CA209-7AL (n = 172) and RWS-cICI cohort (n = 65)
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Consolidation group not reached; RWS-cICI cohort 15.4 months; Observation group 12.8 months. Survival at 12 months: Consolidation group 73%; RWS-cICI cohort 63%; Observation group 54%. Hazard ratio Consolidation group vs Observation group 0.48 (95% CI 0.30–0.76).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Consolidation group | 86 | 27 | not reached |
| RWS-cICI cohort | 65 | 35 | 15.4 |
| Observation group | 86 | 52 | 12.8 |
- Consolidation group vs Observation group: reconstructed HR 0.48 (95% CI 0.30–0.76)
- RWS-cICI cohort vs Observation group: reconstructed HR 0.87 (95% CI 0.57–1.34)
Landmark survival (reconstructed)
| Time | Consolidation group | RWS-cICI cohort | Observation group |
|---|---|---|---|
| 6 mo | 94.7% | 87.1% | 81.8% |
| 12 mo | 72.6% | 62.6% | 54.1% |
| 18 mo | 65.0% | 41.6% | 42.4% |
| 24 mo | 53.1% | 39.2% | 33.7% |
| 36 mo | 53.1% | 39.2% | 31.5% |
Checks against the published figure
- Observation group median: printed 12.2, reconstructed 12.8 pass
- RWS-cICI cohort median: printed 15.7, reconstructed 15.4 pass
- hazard ratio (direction inferred): printed 0.49, reconstructed 0.477 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/ca209-7al-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/ca209-7al-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Signal Transduct Target Ther. 2025 Sep 29;10:317. doi: 10.1038/s41392-025-02408-3 doi:10.1038/s41392-025-02408-3. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/ca209-7al
Report a problem with these data
Related trials
- LUSTRE: Event-free survival; Local control; Overall survival
- PRESERVE-003: Overall survival (OS); Progression-free survival (PFS, investigator assessment)
- KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
- CONVERT: Local progression-free survival; Metastatic progression-free survival; Overall survival
- PIN: Overall survival
- Socazolimab + chemotherapy in extensive-stage SCLC: Overall survival; Progression-free survival (IRRC, RECIST v1.1)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials